Verapamil (versus unexposed)

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)2.51 [1.01, 6.28]-1 study3956not evaluable ROB4.46 [1.08; .]
Limb defects1.89 [0.10, 36.98]-1 study355not evaluable ROB-
Major congenital malformations1.91 [0.42, 8.63]-1 study1655not evaluable ROB-
Neural Tube Defects1.87 [0.11, 32.37]-1 study1,2028not evaluable ROB-

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Preterm (< 37 weeks)2.69 [1.34, 5.44]60%2 studies5970not evaluable ROB4.83 [2.00; .]
Low birth weight (< 2500g)2.61 [1.58, 4.31]-1 study18not evaluable ROB4.66 [2.54; .]

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Caesarean1.76 [1.21, 2.55]-1 study43not evaluable ROB2.92 [1.72; .]

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Low Apgar score (< 7) (NOS)1.58 [0.97, 2.58]-1 study19not evaluable ROB-

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Early intrauterine death (< 22 weeks)0.90 [0.32, 2.57]-1 study6358not evaluable ROB-
Elective/induced termination of pregnancy1.78 [0.61, 5.24]-1 study3462not evaluable ROB-
Late intrauterine deaths (> 22 weeks)2.25 [0.27, 19.02]-1 study758not evaluable ROB-

Hide endpoints reported in only one study ...